# Pizarra — PT-pseudo_249def42388a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_249def42388a
Task: 1

Encounter: Urology - outpatient on 20 Feb 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 78-year-old male
  - PSA: 7.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.236 ng/mL²
  - PSA velocity: 0.84 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 32.25 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.82135016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.6 ng/mL. PI-RADS 5. PSAD 0.24. Prostate volume 32 mL. DRE nodus. csPCa 0.82.

Vitals: weight 104 kg, height 190 cm, BMI 28.8, BP 136/96 mmHg, HR 64 bpm. Smoking: Current smoker (29 pack-yr).

Chief complaint: Persistent PSA elevation alongside recent multiparametric MRI results prompted this clinical evaluation.

History: Now 78 years old, this widowed civil engineer recently retired and moved to the region half a year ago. He shares a home with his sister, while his adult son handles daily logistics and serves as his lasting power of attorney. His prior biopsy bucket remains "None". Lower urinary tract complaints are entirely absent, yielding an IPSS score of zero, and he explicitly denies pelvic discomfort or blood in the urine. His medical background includes well-regulated type 2 diabetes, currently treated with empagliflozin under quarterly diabetes nurse supervision. A substantial 29 pack-yr smoking history is noted, alongside a moderate alcohol consumption pattern of twelve units weekly. He swims once a week to stay fit. Stable osteoarthritis in his right knee is managed with paracetamol, and he recalls a minor appendectomy during his twenties. Otherwise, he reports feeling generally robust.

Physical examination: DRE — texture: firm with a discrete Nodus localized to the left peripheral zone; asymmetry: clearly present. General examination remains unremarkable, recording a blood pressure of 136/96 mmHg, a heart rate of 64 bpm, and a body mass index of 28.8. No abdominal masses or peripheral lymphadenopathy are detected.

Patient info: civil engineer; Widowed; Recently relocated; lives with sister.
Next of kin: Adult son (acts as caregiver, lasting power of attorney).

Lifestyle: alcohol 12 units / week; exercise Swimming 1x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Diabetes nurse — quarterly review.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.77 +/- 0.17   (95% CI 0.37-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 4.6 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=7.6, age=78.0, psad=0.236, dre_ord=1.0, vol=32.25, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the specific PSA velocity (0.84 ng/mL/yr), the prior PSA (5.7 ng/mL), or the full context from the mpMRI report or laboratory panel. These factors are crucial for assessing the rate of change and overall risk profile, which the prior ignored.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy based on a high csPCa probability (0.82135016) and PI-RADS 5. However, the prior does not account for the fact that the prior biopsy status is "None," meaning the decision is purely predictive. Furthermore, the high csPCa probability might be inflated if the DRE finding ("Nodus") is interpreted as benign, which contradicts the high risk suggested by PI-RADS 5. The wide interval (0.37-0.99) suggests high uncertainty, and the prior's reliance on only the structured data might be missing critical clinical context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details suspicious features or extent, it would refine the PI-RADS 5 assessment.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend is rapidly increasing, it would strengthen the case for intervention.
  <document> laboratory results (full panel) -> To check for any other markers that might influence risk stratification.
  <document> previous GP / urology consultation notes -> To see if prior discussions or LUTS history provide context for the DRE finding.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Radiology Division | Catharina Ziekenhuis, Eindhoven | 28 Jan 2025 | Multiparametric MRI Prostate
  Clinical Context: PSA value: 7.6 with clinical suspicion of malignancy.
  FINDINGS:
  prostate volume: 32.25 mL. T2-weighted sequences disclose a sharply demarcated hypointense area within the left peripheral zone, situated at the base-to-mid transition, spanning roughly 18 mm. Diffusion-weighted imaging shows pronounced signal restriction paired with depressed ADC values. Dynamic contrast-enhanced phases highlight early, localized enhancement against adjacent tissue. Extracapsular spread and seminal vesicle involvement are absent. Pelvic lymph nodes appear normal. Skeletal survey reveals no suspicious bony abnormalities.
  IMPRESSION:
  PI-RADS: 5 lesion in the left peripheral zone (base/mid), approximately 18 mm.
  PSA density: 0.236 ng/mL/mL.
  csPCa probability: 0.82135016.

  **psa_trend**
  [{"date": "Jul 2022", "val": 0.6}, {"date": "Mar 2023", "val": 2.0}, {"date": "Oct 2023", "val": 3.0}, {"date": "Jun 2024", "val": 5.9}, {"date": "Feb 2025", "val": 7.6}]

  **lab_results**
  [{"name": "PSA", "val": "7.6 ng/mL", "date": "05 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.20 ng/mL", "date": "05 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "05 Feb 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.8 g/dL", "date": "05 Feb 2025", "flag": ""}, {"name": "WBC", "val": "8.3 x10^9/L", "date": "05 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "298 x10^9/L", "date": "05 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "111 umol/L", "date": "05 Feb 2025", "flag": "H"}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "05 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "14.6 nmol/L", "date": "05 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "71 U/L", "date": "05 Feb 2025", "flag": ""}, {"name": "LDH", "val": "206 U/L", "date": "05 Feb 2025", "flag": ""}]

  **previous_notes**
  [{"date": "03 Mar 2023", "author": "Dr. C. Peters (GP)", "text": "Subsequent visit to review initial screening PSA outcomes. Laboratory data showed a PSA level of 4.3 ng/mL, marking a steady rise from the 4.0 ng/mL measurement documented in July 2022. Diabetes care was reassessed, with empagliflozin therapy maintained. A standard cardiovascular risk evaluation was conducted, accounting for his ongoing tobacco use."}]

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone (base/mid), approximately 18 mm.
  PSA velocity of 0.84 ng/mL/yr (calculated from 5.7 to 7.6 over ~2 years, or from the trend data).
  csPCa probability: 0.82135016.
  
  AGAINST sampling this patient now:
  DRE finding: Nodus (interpreted as potentially benign by the DRE finding itself, despite PI-RADS 5).

WHERE THIS LEANS
  The retrieved evidence strongly supports sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which aligns with the statistical prior's suggestion. The contradiction lies between the high imaging risk and the DRE finding.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the high-risk imaging finding of a PI-RADS 5 lesion in the left peripheral zone and a concerning PSA velocity of 0.84 ng/mL/yr. This is strongly supported by the csPCa probability of 0.82135016 and the rising PSA trend from 5.7 to 7.6 ng/mL. The decision is made despite the DRE finding of a nodus, as the high-risk imaging and PSA kinetics outweigh this finding.

Variables that carried weight: age=noted, dre=important, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
